 This article by Gaurav Dubey was originally published on Microdose Psychedelic Insights and appears here with permission. The psychedelic front-runners at MindMed NASDAQ:MNMD have announced their partnership with BioXcel Therapeutics and published an International Patent Application describing a system for identifying agitation episodes. 